Lung Cancer Liquid Biopsy Market Size & Growth Forecast 2026–2035, By Segments (Sample Type, Technology, Product, Biomarker, End-use, Clinical Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growoth Outlook
Lung Cancer Liquid Biopsy Market size stood at USD 1.19 Billion in 2025 and is predicted to grow at a 13.1% CAGR from 2026 to 2035, exceeding USD 4.08 Billion by 2035. The industry revenue for 2026 is assessed at USD 1.33 billion.
Get more details on this report
Request Free Sample ReportLung Cancer Liquid Biopsy Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for 53.00% of the market in 2025, supported by advanced molecular diagnostics infrastructure, widespread biomarker testing, and established oncology care pathways.
- Asia Pacific is projected to grow at a 14.67% CAGR as healthcare systems expand molecular diagnostics, precision oncology adoption increases, and demand rises for less invasive cancer testing.
Segment Momentum
- Blood sample-based testing held a 67.9% market share in 2025 because it enables routine, repeat monitoring through simple collection, supporting timely molecular assessment and broader clinical adoption with less procedural burden.
- Multi-gene-parallel Analysis (NGS) is growing fastest because it delivers comprehensive genomic profiling from a single sample, improving testing efficiency and supporting therapy selection and ongoing disease management.
Market Expansion Drivers
- Rising global lung cancer prevalence driving demand for early non-invasive diagnostic testing.
- Increasing FDA approvals and companion diagnostics accelerating clinical adoption of liquid biopsy.
- Expanding oncology precision medicine programs improving biomarker-based treatment selection.
Leading Market Participants
Global Market Forecast Snapshot
Market Outlook
Leading players in the lung cancer liquid biopsy market include F. Hoffmann-La Roche Ltd. (Switzerland), Guardant Health, Inc. (United States), Illumina, Inc. (United States), Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Netherlands), Exact Sciences Corporation (United States), Natera, Inc. (United States), Agilent Technologies, Inc. (United States), Bio-Rad Laboratories, Inc. (United States), Myriad Genetics, Inc. (United States).Regional and Segment Outlook
North AmericaMarket Growth Drivers and Industry Trends
As lung cancer case volumes rise globally, care pathways are under growing pressure to identify disease earlier and assess patients who may not be ideal candidates for repeat tissue biopsy. This is strengthening demand for the lung cancer liquid biopsy market because blood-based testing can be integrated more easily into initial workups, follow-up testing, and recurrence monitoring without the procedural burden associated with invasive sampling. In practice, higher patient throughput pushes hospitals, cancer centers, and diagnostic laboratories toward scalable testing approaches that reduce delays in molecular assessment, helping liquid biopsy gain traction where rapid, lower-risk diagnostic decision-making is becoming more important.
Increasing FDA approvals and companion diagnostics accelerating clinical adoption of liquid biopsy
Regulatory clearances and companion diagnostic approvals reduce a major source of hesitation in oncology testing by giving clinicians, laboratories, and payers clearer evidence that specific liquid biopsy assays can be used in defined treatment decisions. For the lung cancer liquid biopsy market, This trends adoption from exploratory use toward routine clinical integration, particularly when test results can directly guide targeted therapy selection. In practice, FDA-backed claims support formulary inclusion, reimbursement discussions, and physician confidence, which increases ordering behavior and encourages health systems to incorporate liquid biopsy into standardized lung cancer testing workflows.
Expanding oncology precision medicine programs improving biomarker-based treatment selection
The expansion of precision oncology programs is increasing the clinical value of fast, comprehensive biomarker profiling, especially in lung cancer where treatment choice often depends on identifying actionable mutations before therapy begins. This is aiding market expansion for the lung cancer liquid biopsy market as institutions build pathways around molecular tumor boards, targeted therapy protocols, and longitudinal genomic monitoring that rely on accessible testing options. Liquid biopsy fits these programs well because it can capture tumor-related genomic information when tissue is limited or unavailable, making biomarker-based treatment selection more practical and helping providers operationalize precision medicine at scale.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising global lung cancer prevalence driving demand for early non-invasive diagnostic testing | 2.40% | High | North America, Asia Pacific | High | Near Term |
| Increasing FDA approvals and companion diagnostics accelerating clinical adoption of liquid biopsy | 2.00% | High | North America, Europe | High | Near Term |
| Expanding oncology precision medicine programs improving biomarker-based treatment selection | 1.80% | High | North America, Asia Pacific | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America held a 53.00% share of the lung cancer liquid biopsy market in 2025, supported by established molecular diagnostics infrastructure, broad access to advanced oncology testing, and routine integration of biomarker-based decision-making into lung cancer care pathways. The region’s leadership is reinforced by the practical use of liquid biopsy in diagnosis support, treatment selection, and disease monitoring, where strong laboratory capacity and clinician familiarity help sustain testing volumes. Market activity also benefits from the concentration of specialized cancer centers and the faster incorporation of innovative diagnostic platforms into clinical workflows.
Asia Pacific is projected to expand at a 14.67% CAGR over the forecast period, with the lung cancer liquid biopsy market gaining momentum as access to cancer diagnostics improves across major healthcare systems and demand rises for less invasive testing approaches. Growth is being propelled by increasing adoption of precision oncology practices, especially in settings where clinicians are seeking faster and more scalable methods for mutation detection and therapy guidance. As diagnostic capabilities continue to broaden and hospitals and laboratories build out molecular testing capacity, regional uptake is accelerating in day-to-day oncology practice.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Molecular Diagnostics FocusGermany is strengthening lung cancer liquid biopsy adoption through investments in advanced molecular diagnostics and precision medicine. Clinical laboratories are emphasizing standardized testing workflows that improve biomarker identification and treatment selection.
France 🇫🇷
Personalized Cancer DiagnosticsFrance is encouraging broader adoption of lung cancer liquid biopsy within precision medicine initiatives. Clinical centers focus on improving access to minimally invasive genomic testing that supports individualized therapeutic decision-making for oncology patients.
Italy 🇮🇹
Oncology Testing ModernizationItaly is modernizing lung cancer diagnostics by incorporating liquid biopsy into oncology care pathways where clinically appropriate. Healthcare providers emphasize faster molecular insights that complement conventional diagnostic methods and support personalized treatment strategies.
Japan 🇯🇵
Biomarker Testing IntegrationJapan is incorporating lung cancer liquid biopsy into oncology care to improve genomic testing efficiency and patient management. Healthcare institutions prioritize accurate biomarker detection that supports targeted therapies while reducing dependence on invasive procedures.
South Korea 🇰🇷
Clinical Genomics ExpansionSouth Korea is increasing the clinical use of lung cancer liquid biopsy to enhance precision oncology programs and genomic profiling capabilities. Hospitals are integrating advanced molecular testing technologies to improve treatment planning and patient monitoring.
United States 🇺🇸
Precision Oncology AdoptionThe U.S. is expanding the use of lung cancer liquid biopsy technologies to support earlier molecular profiling and personalized treatment decisions. Healthcare providers increasingly integrate liquid biopsy into clinical workflows to complement tissue-based diagnostic approaches.
Segment Leadership and Growth Trends
Lung Cancer Liquid Biopsy Market Share (%), Sample Type, 2025
Go beyond the chart, access full insights & data tables
Request Free Sample ReportBlood Sample Based held a 67.9% share of the lung cancer liquid biopsy market in 2025, and it continues to expand fastest because blood remains the most practical sample type for routine testing, repeat monitoring, and broad clinical adoption. Its leadership is underpinned by the ease of collection within standard care pathways, which supports timely molecular assessment without the procedural burden associated with more invasive approaches. That same operational advantage is also driving ongoing growth in the lung cancer liquid biopsy market, as clinicians and testing providers increasingly rely on blood sample based workflows for serial testing, treatment monitoring, and situations where tissue access is limited.
Technology Segment Analysis: Multi-gene-parallel Analysis (NGS) (Largest & Fastest-Growing Segment)
By 2025, Multi-gene-parallel Analysis (NGS) accounted for the largest share of the lung cancer liquid biopsy market and is also advancing at the fastest pace as testing needs shift toward broader genomic profiling from a single sample. Its market lead is underpinned by the practical value of assessing multiple clinically relevant alterations in one run, which improves efficiency when compared with narrower testing approaches. Growth momentum in the lung cancer liquid biopsy market is being reinforced by the same dynamic, as demand rises for comprehensive molecular insights that can better support therapy selection and ongoing disease management without requiring multiple separate assays.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Sample Type | Blood Sample Based, Others | Blood Sample Based | Blood Sample Based |
| Technology | Multi-gene-parallel Analysis (NGS), Single Gene Analysis (PCR Microarrays) | Multi-gene-parallel Analysis (NGS) | Multi-gene-parallel Analysis (NGS) |
| Product | Instruments, Consumables Kits and Reagents, Software and Services | Consumables Kits and Reagents | Instruments |
| Biomarker | Circulating Nucleic Acids, CTC, Exosomes/Microvesicles, Circulating Proteins | Circulating Nucleic Acids | Exosomes/Microvesicles |
| End-use | Hospitals & Laboratories, Specialty Clinics, Academic & Research Centers, Others | Hospitals & Laboratories | Specialty Clinics |
| Clinical Application | Therapy Selection, Treatment Monitoring, Early Cancer Screening, Recurrence Monitoring, Others | Therapy Selection | Early Cancer Screening |
Competitive Landscape and Market Positioning
1. F. Hoffmann-La Roche Ltd. (Switzerland)
2. Guardant Health Inc. (United States)
3. Illumina Inc. (United States)
4. Thermo Fisher Scientific Inc. (United States)
5. QIAGEN N.V. (Netherlands)
6. Exact Sciences Corporation (United States)
7. Natera Inc. (United States)
8. Agilent Technologies Inc. (United States)
9. Bio-Rad Laboratories Inc. (United States)
10. Myriad Genetics Inc. (United States)
The lung cancer liquid biopsy market is progressing through advancements in non-invasive diagnostic techniques. Improved molecular detection methods are enabling earlier and more accurate diagnosis. Collaborative research efforts are accelerating clinical adoption. The lung cancer liquid biopsy market is reshaping oncology diagnostics through precision testing approaches.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| No companies available. | |||||||
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Illumina | Nov-23 | In November 2023, Illumina launched an advanced liquid biopsy assay for detecting non-small-cell lung cancer, expanding its oncology diagnostics portfolio. The assay strengthens its position in blood-based cancer testing by improving access to genomic insights for research and clinical applications, supporting broader adoption of minimally invasive cancer detection approaches. |
| Delfi Diagnostics | Oct-23 | In October 2023, Delfi Diagnostics introduced its first blood-based biopsy test for lung cancer screening, expanding the availability of liquid biopsy tools for early cancer detection. The launch strengthens its position in non-invasive oncology diagnostics by adding a new screening modality to existing blood-based cancer detection approaches. |
| Menarini Silicon Biosystems | Jul-23 | In July 2023, Menarini Silicon Biosystems launched the CellSearch CTC test incorporating the DLL3 biomarker for small cell lung cancer applications. The development expands its liquid biopsy assay portfolio and supports more targeted cancer diagnostics by improving circulating tumor cell analysis for treatment guidance in lung cancer cases. |
| Twist Bioscience Corporation | Feb-24 | In February 2024, Twist Bioscience Corporation introduced a cfDNA library preparation kit designed to support liquid biopsy research workflows. The product enhances genomic sample preparation capabilities for next-generation sequencing applications, contributing to improved efficiency and accuracy in cancer research and liquid biopsy assay development. |
| Guardant Health, Inc. | May-22 | In May 2022, Guardant Health expanded its blood-based cancer testing services in Europe through operational deployment at the Vall d’Hebron Institute of Oncology liquid biopsy facility in Barcelona. The development strengthens access to liquid biopsy diagnostics in clinical research environments and supports broader adoption of blood-based oncology testing in European healthcare settings. |
Explore This Report
Click a section of the wheel — or its numbered marker — to preview the custom segmentation, custom table of contents, or related reports available for this market.
Lung Cancer Liquid Biopsy Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| No segment data available. | |
Lung Cancer Liquid Biopsy Market — report.custom
| Custom Chapter | Custom Details | ||
|---|---|---|---|
| No custom TOC data available. | |||
Need a different cut of the data?
Request Custom ResearchWhat is the current size of the lung cancer liquid biopsy market?
How is the lung cancer liquid biopsy industry size expected to evolve during the forecast period?
How is blood-based sampling shaping routine testing and monitoring workflows in the lung cancer liquid biopsy market?
How is multi-gene NGS testing influencing clinical decision-making in the lung cancer liquid biopsy market?
Why are blood sample-based tests the leading sample type in the lung cancer liquid biopsy market?
Why is Multi-gene-parallel Analysis (NGS) the fastest-growing technology in the lung cancer liquid biopsy market?
Why is North America the largest market for lung cancer liquid biopsy?
What is accelerating lung cancer liquid biopsy adoption in Asia Pacific?
Who are the leading players in the lung cancer liquid biopsy landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source Category | Research Sources | Purpose |
|---|---|---|
| Government Publications | Government agencies, statistical departments, regulatory bodies | Industry statistics, regulatory insights, and policy analysis |
| Company Disclosures | Annual reports, investor presentations, financial filings | Company performance, business strategy, and market positioning |
| Trade Associations | Industry associations and professional organizations | Industry developments, standards, and market perspectives |
| Technical Literature | Research papers, technical publications, academic journals | Technology developments and technical validation |
| Patent Analysis | Patent databases and intellectual property publications | Innovation trends, technology activity, and competitive research |
| Industry Databases | Established research databases and market intelligence resources | Market benchmarking, historical data, and industry analysis |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization